Jaypirca

Approved Uses

Jaypirca is used to treat the following conditions in adults:

• Mantle Cell Lymphoma (MCL): It is used when the cancer has returned or stayed the same after at least two prior types of systemic treatment, including a Bruton tyrosine kinase (BTK) inhibitor.
• Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): It is used for patients who have previously received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

This medication is typically prescribed when other treatments are no longer effective or cannot be tolerated.

Targeting BTK Proteins

Jaypirca belongs to a class of medications known as Bruton's tyrosine kinase (BTK) inhibitors. BTK is a protein found in B-cells, which are a type of white blood cell. In certain cancers, such as mantle cell lymphoma and chronic lymphocytic leukemia, this protein sends signals that tell the cancer cells to grow, multiply, and survive.

How It Stops Cancer Growth

Jaypirca works by binding to the BTK protein and blocking its activity. By shutting down these signals, the medication helps to:

• Interfere with the growth of cancer cells.
• Prevent the cancer from spreading.
• Cause cancer cells to die off.

A Different Way of Binding

Many older BTK inhibitors bind permanently to the protein. Over time, some cancers can change or mutate, preventing those older drugs from working. Jaypirca is a non-covalent inhibitor, meaning it binds to the BTK protein in a reversible and different way. This unique mechanism allows it to continue working even if the cancer has developed resistance to other BTK-targeting treatments.

Common Side Effects

• Fatigue
• Muscle, joint, or bone pain
• Diarrhea
• Swelling in the hands, arms, legs, or feet
• Cough
• Nausea
• Constipation
• Bruising
• Rash

Serious Side Effects

Some side effects can be severe. Seek medical attention if you experience:

• Infections: Fever, chills, or other signs of infection.
• Bleeding: Unusual bruising, nosebleeds, or blood in the stool or urine.
• Heart Rhythm Changes: Palpitations, dizziness, or a racing heart.
• Low Blood Cell Counts: Decreased levels of white blood cells, red blood cells, or platelets.
• New Cancers: Development of new cancers, including skin cancers.

Serious Infections

Treatment with this medication can increase the risk of serious and sometimes fatal infections. These may include bacterial, viral, or fungal infections. Monitoring for signs of infection, such as fever or chills, is important during therapy.

Hemorrhage

There is an increased risk of bleeding, which can range from minor bruising to severe or life-threatening events. The risk may be higher for individuals also taking blood thinners or antiplatelet medications.

Low Blood Cell Counts

This drug can cause a significant decrease in blood cell counts, including:

• Neutropenia: A low level of white blood cells that fight infection.
• Thrombocytopenia: A low level of platelets, which help the blood clot.
• Anemia: A low level of red blood cells.

Regular blood tests are typically performed to monitor these levels.

Heart Rhythm Problems

Some patients may develop heart rhythm issues, such as atrial fibrillation or atrial flutter. Symptoms can include palpitations, dizziness, or shortness of breath.

Second Primary Malignancies

There is a risk of developing other types of cancer, such as skin cancers, while taking this medication. Regular skin examinations may be recommended.

Embryo-Fetal Toxicity

This medication can cause harm to a developing fetus. It is generally recommended that individuals use effective birth control during treatment and for a specific period after the final dose.

Pregnancy

Jaypirca can cause fetal harm when administered to a pregnant woman. Based on animal studies, this medication may lead to birth defects or embryo-fetal toxicity. Healthcare providers typically recommend a pregnancy test before starting treatment for individuals who are able to become pregnant.

If you are a person of reproductive potential, you should use effective birth control during treatment and for at least one week after your final dose. If you become pregnant or think you might be pregnant while taking this medication, notify your healthcare provider immediately.

Breastfeeding

It is not known whether Jaypirca passes into human breast milk. Because of the potential for serious adverse reactions in a breastfed child, you should not breastfeed during treatment and for at least one week after your last dose.

Fertility

Based on findings from animal studies, Jaypirca may impair fertility in both males and females of reproductive potential. If you have concerns about your ability to have children in the future, discuss these risks with your doctor before starting treatment.

Dosage Forms

Jaypirca is supplied as a tablet for oral administration. These tablets are designed to be swallowed whole and should not be crushed, chewed, or broken.

FDA Approval History

Jaypirca received its initial accelerated approval from the U.S. Food and Drug Administration (FDA) in January 2023. This approval was specifically for adults with mantle cell lymphoma (MCL) whose disease had returned or progressed after at least two prior treatments, including another type of Bruton tyrosine kinase (BTK) inhibitor.

In December 2023, the FDA granted accelerated approval for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This was later converted to a traditional approval in August 2024 for adult patients with CLL or SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

Approved Indications

The FDA has approved Jaypirca for the following specific uses:

• Mantle Cell Lymphoma (MCL): For adult patients whose cancer has come back or did not respond to at least two prior lines of systemic therapy, which must have included a BTK inhibitor.
• Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): For adult patients who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

The approval for mantle cell lymphoma was granted under the FDA's accelerated approval pathway, which allows for earlier approval of drugs that treat serious conditions and fill an unmet medical need based on initial clinical data. Continued approval for this specific use may be contingent upon results from further clinical trials to verify the drug's clinical benefit.

Regulatory Requirements

There are currently no boxed warnings or Risk Evaluation and Mitigation Strategies (REMS) programs required by the FDA for Jaypirca. The medication is available by prescription only and is monitored by the FDA for ongoing safety and efficacy through post-marketing surveillance and confirmatory clinical trials.

Insurance Coverage

Jaypirca is a prescription medication used to treat specific types of blood cancer. Most insurance plans, including Medicare Part D, typically cover this medication, though the specific out-of-pocket cost will depend on your individual plan's formulary and tier structure. Your insurance provider may require a prior authorization process before covering the cost.

Specialty Pharmacy Requirements

Because Jaypirca is a specialized oncology treatment, it is often only available through specialty pharmacies. These pharmacies are equipped to handle medications that require specific management or monitoring. They can also assist with navigating insurance claims and identifying potential financial support.

Financial Assistance

There may be programs available to help manage the cost of Jaypirca:

• Co-pay Assistance: Eligible patients with commercial insurance may be able to use co-pay cards provided by the manufacturer to reduce their monthly expenses.
• Patient Assistance Programs: For patients without insurance or those who are underinsured, there may be programs that provide the medication at a reduced cost or for free based on financial need.

The total price of treatment is also influenced by the dosage prescribed and how long the medication is taken.